Agreement to Bring Rapid, Oral HCV Test Outside the U.S. | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

How Grapefruit Reduces the Spread of HCV

Back to News Homepage
Next

Update: What You Need to Know About Grapefruit and Hepatitis C

Agreement to Bring Rapid, Oral HCV Test Outside the U.S.

The Editors at Hepatitis Central
February 26, 2008

Print this page

Two big pharmaceutical companies, Schering-Plough and OraSure, have agreed to work together to deliver a rapid, oral Hepatitis C test. In addition to their collaboration within the United States, this new agreement focuses on bringing this technology to additional markets.

AFX News Limited

Schering-Plough, OraSure Tech collaborate on oral hepatitis C test outside U.S.
www.forbes.com
02.11.08, 9:41 AM ET

NEW YORK (Thomson Financial) – Schering-Plough Corp. and OraSure Technologies Inc. Monday agreed to collaborate on the development and promotion of an oral hepatitis C virus (HCV) test outside the U.S.

The test will use OraSure’s OraQuick technology platform.

Under the agreement Schering-Plough (nyse: SGP – news – people ) will reimburse OraSure for certain development costs and will provide payments to OraSure based on the achievement of certain regulatory and commercial milestones in international markets.

Schering-Plough will provide promotional support while OraSure will make all sales and retain the rights to market and sell the test in all markets throughout the world.

The agreement builds upon the existing collaboration announced in January 2007 to develop and promote a rapid oral HCV test in the U.S. physicians’ office market.
‘We believe the global market opportunity for a rapid HCV test is significant and this expansion of our collaboration with Schering-Plough should help drive the adoption of this important product around the world,’ OraSure said.

OraSure is a Bethlehem, Pa.-based company that specializes in oral fluid specimen collection devices and diagnostic products. Its stock closed Friday at $7.61.
Shares of Schering-Plough, a Kenilworth, N.J.-based advanced drug therapy company, closed Friday at $19.77.

Melinda Peer
mp/pc
Copyright Thomson Financial News Limited 2007. All rights reserved.

No Comments - be the first!
Share
Share
Previous

How Grapefruit Reduces the Spread of HCV

Back to News Homepage
Next

Update: What You Need to Know About Grapefruit and Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.